Adjuvant treatment recommendations (e.g., endocrine treatment, HER2-targeted treatment, chemotherapy, radiotherapy) depend on patient (age, co-morbidities) and tumor characteristics (size, grade, nodal status, tumor subtype). Here, ERBB2 is linked to neoplasm.